1456 – 17p Deletion Testing for Access to Venetoclax in Patients with Relapsed/Refractory Chronic Lymphoid Leukaemia

Page last updated: 29 September 2017

Application Detail



Description of Medical Service

Venetoclax is a BCL-2 inhibitor listed on the Australian Register of Therapeutic Goods (ARTG). The TGA-approved indications are as a treatment for:
• Patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) with 17p-del, or
• Patients with relapsed or refractory CLL for whom there are no other suitable treatment options.

Description of Medical Condition

Chronic lymphoid leukaemia (CLL), which is also known as B-cell Chronic lymphoid leukaemia (B-CLL), is a specific type of leukaemia, a group of cancers usually originated in bone marrow and resulting in abnormally high numbers of white blood cells. The presence of a 17p deletion is associated with a significantly poorer prognosis, and patients harbouring a 17p deletion show marked resistance to genotoxic chemotherapies recommended as first-line treatment for CLL.

Reason for Application

Amendment to MBS item

Medical Service Type

Co-dependent technology

Previous Application Number

Not Applicable

Associated Documentation

Application Form


PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document (PDF 232 KB)
Public Summary Document (Word 88 KB)

Meetings for this Application




8 June 2017


6 - 7 April 2017
27 July 2017